50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Why I Sued the Gov’t – And What I Recommend Now (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Why I Sued the Gov’t – And What I Recommend Now (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Why I Sued the Gov’t – And What I Recommend Now (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis
S&P 500   3,655.04
DOW   29,260.81
QQQ   274.37
This Device Makes Creating Voice Memos Easy
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Three Consumer Stocks That Could Outperform In Q4 
Will Synthetic Biology Firm Amyris Post Net Income In 2024?
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Comcast is an Asset Bonanza Priced Cheap
British pound plunges to new low as tax cuts spark concern
Why I Sued the Gov’t – And What I Recommend Now (Ad)
US stocks slip deeper into a slump as recession fears grow
Lights out, ovens off: Europe preps for winter energy crisis

ANI Pharmaceuticals - ANIP Stock Forecast, Price & News

$31.22
-0.49 (-1.55%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$30.86
$32.04
50-Day Range
$31.22
$38.01
52-Week Range
$22.31
$60.23
Volume
54,715 shs
Average Volume
109,135 shs
Market Capitalization
$544.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.00

ANI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
79.4% Upside
$56.00 Price Target
Short Interest
Bearish
5.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$673,044 Sold Last Quarter
Proj. Earnings Growth
276.92%
From $0.65 to $2.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

400th out of 1,069 stocks

Pharmaceutical Preparations Industry

179th out of 533 stocks

ANIP stock logo

About ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Stock News Headlines

ANI Pharmaceuticals Appoints Krista Davis as...
Full-Year 2022 Guidance:
ANI Pharmaceuticals Q2 2022 Earnings Preview
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANIP Company Calendar

Last Earnings
8/08/2022
Today
9/27/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
601
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.00
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+79.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-42,600,000.00
Pretax Margin
-32.90%

Debt

Sales & Book Value

Annual Sales
$216.14 million
Cash Flow
$4.64 per share
Book Value
$19.73 per share

Miscellaneous

Free Float
12,694,000
Market Cap
$544.38 million
Optionable
Optionable
Beta
1.00

Key Executives

  • Mr. Nikhil LalwaniMr. Nikhil Lalwani (Age 44)
    Pres, CEO & Director
    Comp: $2.17M
  • Mr. Stephen P. CareyMr. Stephen P. Carey (Age 51)
    CFO, Sr. VP of Fin. & Corp. Sec.
    Comp: $1.11M
  • Mr. James G. Marken (Age 59)
    Sr. VP of Operations & Product Devel.
    Comp: $709.02k
  • Mr. Christopher K. Mutz (Age 50)
    Head of Rare Disease
    Comp: $643.58k
  • Mr. Ori Gutwerg (Age 48)
    Sr. VP of Generics
    Comp: $710.74k
  • Mr. Muthusamy Shanmugam MS R.Ph.Mr. Muthusamy Shanmugam MS R.Ph. (Age 54)
    Head of R&D, COO of Novitium Operations & Director
  • Ms. Meredith W. Cook
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Chad Gassert (Age 46)
    Sr. VP of Corp. Devel. & Strategy
  • Ms. Elizabeth Powell J.D.
    Chief Compliance Officer & Head of Legal of Rare Disease
  • Dr. Mary Pao M.D.
    Ph.D., Chief Medical Officer of Rare Disease













ANIP Stock - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month price targets for ANI Pharmaceuticals' stock. Their ANIP share price forecasts range from $48.00 to $70.00. On average, they expect the company's share price to reach $56.00 in the next twelve months. This suggests a possible upside of 79.4% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2022?

ANI Pharmaceuticals' stock was trading at $46.08 on January 1st, 2022. Since then, ANIP shares have decreased by 32.2% and is now trading at $31.22.
View the best growth stocks for 2022 here
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings data on Monday, August, 8th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company had revenue of $73.86 million for the quarter, compared to analysts' expectations of $71 million. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 3.68% and a negative net margin of 25.32%. During the same quarter in the previous year, the firm posted $0.49 EPS.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, September, 6th. The company provided earnings per share (EPS) guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.43. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $304.50 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include William Blair Investment Management LLC (3.23%), State Street Corp (2.67%), Emerald Advisers LLC (2.64%), Thompson Siegel & Walmsley LLC (2.53%), Emerald Mutual Fund Advisers Trust (2.07%) and Global Alpha Capital Management Ltd. (1.88%). Insiders that own company stock include James G Marken, Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $31.22.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals (NASDAQ:ANIP) has a market capitalization of $544.38 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42,600,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

The company employs 601 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The official website for the company is www.anipharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at ir@anipharmaceuticals.com, or via fax at 218-634-3540.

This page (NASDAQ:ANIP) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.